$NARI
Inari Medical Inc

2022 Q1 Form 10-Q Financial Statement

#000095017022007406 Filed on May 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q3 2021 Q1
Revenue $86.75M $72.92M $57.40M
YoY Change 51.14% 88.34% 112.95%
Cost Of Revenue $9.967M $7.040M $4.623M
YoY Change 115.6% 118.09% 70.84%
Gross Profit $76.79M $65.88M $52.77M
YoY Change 45.5% 85.63% 117.65%
Gross Profit Margin 88.51% 90.35% 91.95%
Selling, General & Admin $63.73M $56.10M $36.90M
YoY Change 72.72% 143.08% 125.08%
% of Gross Profit 83.0% 85.17% 69.92%
Research & Development $16.14M $12.50M $8.163M
YoY Change 97.66% 139.58% 170.48%
% of Gross Profit 21.01% 18.97% 15.47%
Depreciation & Amortization $1.063M $820.0K $609.0K
YoY Change 74.55% 127.78% 122.26%
% of Gross Profit 1.38% 1.24% 1.15%
Operating Expenses $79.87M $68.60M $45.06M
YoY Change 77.24% 142.44% 132.14%
Operating Profit -$3.082M -$2.727M $7.713M
YoY Change -139.96% -137.93% 59.49%
Interest Expense $73.00K $73.00K $73.00K
YoY Change 0.0% -70.92% -78.9%
% of Operating Profit 0.95%
Other Income/Expense, Net -$47.00K -$16.00K -$46.00K
YoY Change 2.17% -97.69% -93.65%
Pretax Income -$3.129M -$2.743M $7.667M
YoY Change -140.81% -142.23% 86.45%
Income Tax $0.00 $61.00K $198.0K
% Of Pretax Income 2.58%
Net Earnings -$3.129M -$2.804M $7.469M
YoY Change -141.89% -143.17% 81.64%
Net Earnings / Revenue -3.61% -3.85% 13.01%
Basic Earnings Per Share -$0.06 -$0.06 $0.15
Diluted Earnings Per Share -$0.06 -$0.06 $0.13
COMMON SHARES
Basic Shares Outstanding 50.95M 50.00M 49.36M
Diluted Shares Outstanding 50.95M 50.95M 55.72M

Balance Sheet

Concept 2022 Q1 2021 Q3 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $338.7M $162.6M $174.1M
YoY Change 94.55% -3.22% 437.35%
Cash & Equivalents $186.6M $81.16M $102.9M
Short-Term Investments $152.2M $81.44M $71.20M
Other Short-Term Assets $5.849M $7.141M $2.200M
YoY Change 165.86% 104.03% 214.29%
Inventory $23.83M $19.50M $13.70M
Prepaid Expenses
Receivables $44.95M $38.92M $31.30M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $413.3M $228.2M $221.3M
YoY Change 86.78% 14.36% 318.34%
LONG-TERM ASSETS
Property, Plant & Equipment $18.15M $14.75M $7.600M
YoY Change 138.86% 168.15% 105.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $6.002M
YoY Change
Other Assets $6.216M $672.0K $5.700M
YoY Change 9.05% -25.33% 96.55%
Total Long-Term Assets $70.77M $64.28M $13.30M
YoY Change 432.11% 920.27% 101.52%
TOTAL ASSETS
Total Short-Term Assets $413.3M $228.2M $221.3M
Total Long-Term Assets $70.77M $64.28M $13.30M
Total Assets $484.1M $292.4M $234.6M
YoY Change 106.36% 42.09% 294.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.066M $5.083M $5.500M
YoY Change 10.29% 45.23% 89.66%
Accrued Expenses $29.51M $24.43M $15.10M
YoY Change 95.46% 126.18% 155.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $35.58M $29.51M $20.62M
YoY Change 72.59% 106.36% 136.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $1.416M $28.55M $400.0K
YoY Change 254.0% -75.0%
Total Long-Term Liabilities $1.416M $28.55M $400.0K
YoY Change 254.0% -98.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.58M $29.51M $20.62M
Total Long-Term Liabilities $1.416M $28.55M $400.0K
Total Liabilities $65.30M $58.06M $21.00M
YoY Change 210.94% 305.23% -47.37%
SHAREHOLDERS EQUITY
Retained Earnings -$20.71M -$18.69M
YoY Change -45.68%
Common Stock $440.3M $253.3M $233.7M
YoY Change 88.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $418.8M $234.4M $213.6M
YoY Change
Total Liabilities & Shareholders Equity $484.1M $292.4M $234.6M
YoY Change 106.36% 42.09% 294.29%

Cashflow Statement

Concept 2022 Q1 2021 Q3 2021 Q1
OPERATING ACTIVITIES
Net Income -$3.129M -$2.804M $7.469M
YoY Change -141.89% -143.17% 81.64%
Depreciation, Depletion And Amortization $1.063M $820.0K $609.0K
YoY Change 74.55% 127.78% 122.26%
Cash From Operating Activities -$9.100M -$5.589M $8.766M
YoY Change -203.81% -204.47% -1391.02%
INVESTING ACTIVITIES
Capital Expenditures $2.745M -$4.741M $1.265M
YoY Change 117.0% 185.6% 107.72%
Acquisitions
YoY Change
Other Investing Activities -$70.77M -$2.687M -$21.25M
YoY Change 233.02%
Cash From Investing Activities -$73.51M -$7.428M -$22.51M
YoY Change 226.56% 347.47% 3596.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 176.5M 2.993M 2.214M
YoY Change 7873.89% -109.8% -77.91%
NET CHANGE
Cash From Operating Activities -9.100M -5.589M 8.766M
Cash From Investing Activities -73.51M -7.428M -22.51M
Cash From Financing Activities 176.5M 2.993M 2.214M
Net Change In Cash 93.80M -10.02M -11.71M
YoY Change -900.79% -62.65% -234.12%
FREE CASH FLOW
Cash From Operating Activities -$9.100M -$5.589M $8.766M
Capital Expenditures $2.745M -$4.741M $1.265M
Free Cash Flow -$11.85M -$848.0K $7.501M
YoY Change -257.91% -112.1% -682.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6555000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3836000
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53125434
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
186556000
us-gaap Defined Contribution Plan Tax Status Extensible List
DefinedContributionPlanTaxStatusExtensibleList
http://fasb.org/us-gaap/2021-01-31#QualifiedPlanMember
CY2022Q1 us-gaap Defined Contribution Plan Tax Status Extensible List
DefinedContributionPlanTaxStatusExtensibleList
http://fasb.org/us-gaap/2021-01-31#QualifiedPlanMember
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001531048
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-39293
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Inari Medical, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2902923
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
6001 Oak Canyon
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92618
CY2022Q1 dei City Area Code
CityAreaCode
877
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
923-4747
CY2022Q1 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
CY2022Q1 dei Trading Symbol
TradingSymbol
NARI
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92752000
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
152156000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
83348000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
44950000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
42351000
CY2022Q1 us-gaap Inventory Net
InventoryNet
23828000
CY2021Q4 us-gaap Inventory Net
InventoryNet
21053000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5849000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5694000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
413339000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
245198000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18153000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16471000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6066000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46401000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44909000
CY2022Q1 nari Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
6216000
CY2021Q4 nari Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
981000
CY2022Q1 us-gaap Long Term Investments
LongTermInvestments
0
CY2022Q1 us-gaap Assets
Assets
484109000
CY2021Q4 us-gaap Assets
Assets
311542000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
3983000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6541000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19729000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
24433000
CY2022Q1 nari Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9155000
CY2021Q4 nari Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
10737000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
630000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
802000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
35580000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
42513000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28301000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28404000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1416000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1416000
CY2022Q1 us-gaap Liabilities
Liabilities
65297000
CY2021Q4 us-gaap Liabilities
Liabilities
72333000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53022905
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53022905
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50313452
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50313452
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
53000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
50000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
440238000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
257144000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-767000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-402000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20712000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17583000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
418812000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
239209000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
484109000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
311542000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
86752000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57397000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9967000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4623000
CY2022Q1 us-gaap Gross Profit
GrossProfit
76785000
CY2021Q1 us-gaap Gross Profit
GrossProfit
52774000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16135000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8163000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
63732000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36898000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
79867000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
45061000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3082000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
7713000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
50000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
68000
CY2022Q1 us-gaap Interest Expense
InterestExpense
73000
CY2021Q1 us-gaap Interest Expense
InterestExpense
73000
CY2022Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
24000
CY2021Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
41000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-47000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-46000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3129000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7667000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
198000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3129000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
7469000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-117000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-180000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-248000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
18000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-365000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-162000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3494000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7307000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50954715
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49355945
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50954715
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55722293
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
239209000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
345000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3427000
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-1624000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
11900000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
174394000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6555000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-365000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3129000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
418812000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
200254000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
381000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1882000
CY2021Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-49000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3836000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-162000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
7469000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
213611000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-3129000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
7469000
CY2022Q1 us-gaap Depreciation
Depreciation
1063000
CY2021Q1 us-gaap Depreciation
Depreciation
609000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
36000
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
36000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
604000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
177000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6555000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3836000
CY2022Q1 us-gaap Loans And Leases Receivable Allowance
LoansAndLeasesReceivableAllowance
79000
CY2021Q1 us-gaap Loans And Leases Receivable Allowance
LoansAndLeasesReceivableAllowance
139000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2695000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3437000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2788000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3073000
CY2022Q1 nari Increase Decrease In Prepaid Expenses Deposits And Other Assets
IncreaseDecreaseInPrepaidExpensesDepositsAndOtherAssets
-261000
CY2021Q1 nari Increase Decrease In Prepaid Expenses Deposits And Other Assets
IncreaseDecreaseInPrepaidExpensesDepositsAndOtherAssets
2908000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-467000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2473000
CY2022Q1 nari Increase Decrease In Payroll Related Accruals Accrued Expenses And Other Liabilities
IncreaseDecreaseInPayrollRelatedAccrualsAccruedExpensesAndOtherLiabilities
-6247000
CY2021Q1 nari Increase Decrease In Payroll Related Accruals Accrued Expenses And Other Liabilities
IncreaseDecreaseInPayrollRelatedAccrualsAccruedExpensesAndOtherLiabilities
3635000
CY2022Q1 nari Lease Prepayments For Lessors Owned Leasehold Improvements
LeasePrepaymentsForLessorsOwnedLeaseholdImprovements
-2097000
CY2021Q1 nari Lease Prepayments For Lessors Owned Leasehold Improvements
LeasePrepaymentsForLessorsOwnedLeaseholdImprovements
0
CY2022Q1 nari Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-275000
CY2021Q1 nari Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-190000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9100000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8766000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2745000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1265000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
112073000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
21246000
CY2022Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
5693000
CY2021Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
47000000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-73511000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22511000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
11900000
CY2022Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
174394000
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2022Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3427000
CY2021Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1882000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
345000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
381000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1624000
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
49000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
176542000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2214000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-127000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-183000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
93804000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11714000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92752000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114617000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
186556000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
102903000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
89000
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
118000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
37000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
37000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management Estimates</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements may include, but are not limited to, collectability of receivables, recoverability of long-lived assets, valuation of inventory, other investments, fair v</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">alue of stock options, recoverability of net deferred tax assets and related valuation allowance, and certain accruals. Estimates are based on historical experience and on various assumptions that the Company believes are reasonable under current circumstances. Actual results could differ materially from those estimates. Management periodically evaluates such estimates and assumptions, and they are adjusted prospectively based upon such periodic evaluation.</span></p>
CY2022Q1 us-gaap Other Investments
OtherInvestments
5700000
CY2022Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
272988000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
274000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
272717000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
135949000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
37000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
135926000
CY2022Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
330000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
285000
CY2022Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6521000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5763000
CY2022Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1676000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1490000
CY2022Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
15631000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
13800000
CY2022Q1 us-gaap Inventory Net
InventoryNet
23828000
CY2021Q4 us-gaap Inventory Net
InventoryNet
21053000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23953000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21252000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5800000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4781000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18153000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16471000
CY2021Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P4M
CY2020Q4 nari Operating Leases Number Of Lease Period Extension Options
OperatingLeasesNumberOfLeasePeriodExtensionOptions
2
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
42200000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
28600000
CY2020Q4 nari Tenant Allowance
TenantAllowance
13500000
CY2020Q4 nari Tenant Allowance Related To Prepaid Lease Payments
TenantAllowanceRelatedToPrepaidLeasePayments
3700000
CY2022Q1 nari Number Of Letter Of Credit
NumberOfLetterOfCredit
2
CY2021Q4 nari Number Of Letter Of Credit
NumberOfLetterOfCredit
2
CY2020Q4 nari Prepaid Operatingleasepayments
PrepaidOperatingleasepayments
4900000
CY2020Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P232M
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2021Q3 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
714000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1043000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
15000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
139000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1828000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2163000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2234000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2295000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2361000
CY2022Q1 nari Lessee Operating Lease Liability Payments Thereafter
LesseeOperatingLeaseLiabilityPaymentsThereafter
39536000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
50417000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
21486000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
28931000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
630000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28301000
CY2022Q1 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
29000
CY2021Q1 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
29000
CY2022Q1 nari Research And Development Expense Accrued
ResearchAndDevelopmentExpenseAccrued
2500000
CY2022Q1 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
430000
CY2021Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
430000
CY2022Q1 us-gaap Accumulated Amortization Deferred Finance Costs
AccumulatedAmortizationDeferredFinanceCosts
227000
CY2021Q4 us-gaap Accumulated Amortization Deferred Finance Costs
AccumulatedAmortizationDeferredFinanceCosts
191000
CY2022Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
203000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
239000
CY2022Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
174400000
CY2022Q1 nari Underwriters Discounts And Commissions Expenses
UnderwritersDiscountsAndCommissionsExpenses
11200000
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
700000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
67600000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
CY2022Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
54808
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
503135
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3129000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7667000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
198000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3129000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
7469000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.026
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17900000
CY2022Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q1 us-gaap Significant Change In Unrecognized Tax Benefits Nature Of Event
SignificantChangeInUnrecognizedTaxBenefitsNatureOfEvent
It is not expected that there will be a significant change in uncertain tax position in the next twelve months.
CY2022Q1 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
In the normal course of business, the Company is subject to examination by tax authorities. As of the date of the financial statements, there are no tax examinations in progress. The statute of limitations for tax years ended after December 31, 2015 and December 31, 2016 are open for state and federal tax purposes, respectively.
CY2022Q1 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
1.00
CY2022Q1 us-gaap Defined Benefit Plan Plan Assets Contributions By Plan Participant
DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
1.00
CY2022Q1 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.04
CY2022Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1700000
CY2021Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
800000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3129000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
7469000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50954715
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49355945
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50954715
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55722293
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5901289

Files In Submission

Name View Source Status
0000950170-22-007406-index-headers.html Edgar Link pending
0000950170-22-007406-index.html Edgar Link pending
0000950170-22-007406.txt Edgar Link pending
0000950170-22-007406-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nari-20220331.htm Edgar Link pending
nari-20220331.xsd Edgar Link pending
nari-20220331_cal.xml Edgar Link unprocessable
nari-20220331_def.xml Edgar Link unprocessable
nari-20220331_htm.xml Edgar Link completed
nari-20220331_lab.xml Edgar Link unprocessable
nari-20220331_pre.xml Edgar Link unprocessable
nari-ex31_1.htm Edgar Link pending
nari-ex31_2.htm Edgar Link pending
nari-ex32_1.htm Edgar Link pending
nari-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending